En Carta Diagnostics, a Paris, France-based startup developing rapid point-of-care (POC) molecular diagnostics kits, raised €1.5M in Pre-Seed funding.
The round was led by CentraleSupélec Venture with participation from undisclosed angles.
The company intends to use the funds to develop a diagnostic kit, with the purpose of autonomously detecting Lyme disease within minutes and to implement its go-to-market strategy.
Led by CEO Guillaume Horreard, En Carta provides a rapid Point-of-Care diagnostic platform, in a frugal cassette format. It uses aptamers, capable of binding with high affinity and specificity to a predetermined target. This ‘signature’ can be programmed to detect any genetic, pathogenic or veterinary indication, opening up an extensive range of applications.
The company is addressing Lyme disease as its first application, due to this disorder’s escalation as the most prevalent vector-borne disease in the Northern Hemisphere – with 1.2M cases recorded annually.
En Carta expects to present preclinical data in early 2025.
FinSMEs
22/05/2024